Morepen Laboratories logo

Morepen Laboratories MD, chairman, board of directors and AGM

NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap

Last close ₹123.54up ₹5.87 (4.99%)BSE ₹123.25

Share price at the NSE close on 23 Oct 2026. Previous close ₹117.67.

52-week range of traded prices to 23 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
Market cap
₹6,769 Cr1,108th largest listed
P/E
48.2
P/E without one-offs
59.0
P/B
5.4
Dividend yield
0.16%
ROE
11.7%
ROE without one-offs
9.5%
ROCE
10.3%
Debt to equity
0.16
Volume, NSE
50,63,581

Morepen Laboratories board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • Chairperson and managing directorSUSHIL SURIRelated to the promoter
  • Managing directorSANJAY SURI
  • Company Secretary and Compliance OfficerVipul Kumar Srivastava

6 directors4 independent2 executive

  • SUSHIL SURI · Chairperson and managing directorExecutive · joined Apr 1992 · reappointed Oct 2023 · 1 listed board · 1 committee seat
  • SANJAY SURI · Managing directorExecutive · joined Aug 2019 · reappointed Jul 2026 · 1 listed board
  • PRAVEEN KUMAR DUTTIndependent · joined Aug 2019 · reappointed Aug 2024 · 85 months as independent · 1 listed board · 1 as independent · 2 committee seats, 2 as chair
  • RANJIT KHATTARIndependent · joined Aug 2024 · reappointed Aug 2024 · 25 months as independent · 1 listed board · 1 as independent · 3 committee seats, 2 as chair
  • SHARAD JAINIndependent · joined Aug 2024 · reappointed Aug 2024 · 25 months as independent · 1 listed board · 1 as independent · 2 committee seats
  • SAVITAIndependent · joined Jun 2020 · reappointed Jun 2025 · 75 months as independent · 3 listed boards · 3 as independent · 6 committee seats, 1 as chair

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 4 Aug 20266 of 6 present4 independent · 34 days in between
    • 30 Jun 20264 of 6 present4 independent · 34 days in between
    • 26 May 20266 of 6 present4 independent · 5 days in between
    • 20 May 20265 of 6 present3 independent

  • Audit Committee

    Chair PRAVEEN KUMAR DUTT

    RANJIT KHATTAR, SHARAD JAIN

    • 4 Aug 20263 of 3 present3 independent · 69 days in between
    • 26 May 20263 of 3 present3 independent · 5 days in between
    • 20 May 20262 of 3 present2 independent · 39 days in between
    • 10 Apr 20262 of 3 present2 independent

  • Nomination and remuneration committee

    Chair PRAVEEN KUMAR DUTT

    RANJIT KHATTAR

    • 4 Aug 20263 of 3 present3 independent · 34 days in between
    • 30 Jun 20263 of 3 present3 independent

  • Stakeholders Relationship Committee

    Chair PRAVEEN KUMAR DUTT

    SUSHIL SURI, SAVITA

    • 26 Sep 20262 of 3 present1 independent · 4 days in between
    • 21 Sep 20262 of 3 present1 independent · 6 days in between
    • 14 Sep 20262 of 3 present1 independent · 6 days in between
    • 7 Sep 20262 of 3 present1 independent · 6 days in between
    18 earlier meetings
    • 31 Aug 20262 of 3 present1 independent · 6 days in between
    • 24 Aug 20262 of 3 present1 independent · 6 days in between
    • 17 Aug 20262 of 3 present1 independent · 6 days in between
    • 10 Aug 20262 of 3 present1 independent · 5 days in between
    • 4 Aug 20263 of 3 present2 independent · no day in between
    • 3 Aug 20262 of 3 present1 independent · 6 days in between
    • 27 Jul 20262 of 3 present1 independent · 6 days in between
    • 20 Jul 20262 of 3 present1 independent · 6 days in between
    • 13 Jul 20262 of 3 present1 independent · 6 days in between
    • 6 Jul 20262 of 3 present1 independent · 5 days in between
    • 30 Jun 20262 of 3 present1 independent · 7 days in between
    • 22 Jun 20262 of 3 present1 independent · 6 days in between
    • 15 Jun 20262 of 3 present1 independent · 19 days in between
    • 26 May 20263 of 3 present2 independent · 14 days in between
    • 11 May 20262 of 3 present1 independent · 6 days in between
    • 4 May 20262 of 3 present1 independent · 6 days in between
    • 27 Apr 20262 of 3 present1 independent · 6 days in between
    • 20 Apr 20262 of 3 present1 independent

  • Risk Management Committee

    Chair PRAVEEN KUMAR DUTT

    SUSHIL SURI, RANJIT KHATTAR

    • 26 May 20263 of 3 present2 independent

  • Corporate Social Responsibility Committee

    Chair SUSHIL SURI

    PRAVEEN KUMAR DUTT, SAVITA

    • 4 Aug 20263 of 3 present2 independent

  • Finance Committee

    Chair SUSHIL SURI

    PRAVEEN KUMAR DUTT, SANJAY SURI

    • 6 Aug 20263 of 3 present1 independent · 104 days in between
    • 23 Apr 20263 of 3 present1 independent

  • QIP Issue Committee

    Chair PRAVEEN KUMAR DUTT

    RANJIT KHATTAR, SHARAD JAIN

    • 7 Apr 20262 of 3 present2 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Mar 2026.

  • S P Babuta & AssociatesPeer-review certificate valid to Jun 2028

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Morepen Laboratories AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Morepen Laboratories dividend history

Annual general meeting, 26 Sep 2026

4,02,591 shareholders on the register on 19 Sep 2026; present: 32 promoters and 60 others; votes counted by Praveen Dua / P D and Associates.The company's voting result (opens in a new tab)

  1. Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2026 together with the reports of the Directors' and Auditors' thereon.MoreLess
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 43.81% · promoters 99.79% · institutions 21.14% · other public 12.12%

  2. Declaration of the final dividend of ₹0.20/- per equity share of the face value of ₹2/- each, for the financial year ended 31st March 2026.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 43.84% · promoters 99.79% · institutions 21.72% · other public 12.12%

  3. Appointment of a Director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for reappointment.
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 43.84% · promoters 99.79% · institutions 21.72% · other public 12.12%

  4. Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company, for the financial year 2026-27
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 43.84% · promoters 99.79% · institutions 21.72% · other public 12.12%

  5. Elevation and change in designation of Mr. Sanjay Suri (DIN: 00041590) from Whole-Time Director to Managing Director.
    SpecialPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.26% · other public 0.02%

    Turnout: all 42.83% · promoters 96.97% · institutions 21.72% · other public 12.12%

  6. Re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director.
    SpecialPromoters have an interest in it
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 1.66% · other public 0.01%

    Turnout: all 42.61% · promoters 96.36% · institutions 21.72% · other public 12.12%

  7. Extension of approved timeline for hiving off Medical Devices Business of the company, a material related party transaction, into Morepen Medipath Limited (formerly Morepen Medtech Limited), subsidiary company as a going concern on slump sale basisMoreLess
    SpecialPromoters have an interest in it
    87.49% for12.51% against

    Against: promoters 0.00% · institutions 99.37% · other public 0.04%

    Turnout: all 8.26% · promoters 0.00% · institutions 21.72% · other public 12.12%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 6 Sep 2025, 11 resolutions

4,62,039 shareholders on the register on 30 Aug 2025; present: 29 promoters and 50 others; votes counted by Praveen Dua / P D and Associates.The company's voting result (opens in a new tab)

  1. Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2025 together with the reports of the Directors' and Auditors' thereon.MoreLess
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 43.72% · promoters 99.79% · institutions 26.51% · other public 11.91%

  2. Declaration of the final dividend of ₹0.20/- per equity share of the face value of ₹2/- each, for the financial year ended 31st March 2025.
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.04%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

  3. Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for reappointment.
    OrdinaryPromoters have an interest in it
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.25%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

  4. Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.07%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

  5. Appointment of M/s. PD and Associates, Company Secretaries as Secretarial Auditor of the company for a term of five (5) consecutive years and fixation of remuneration thereof.
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.24%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

  6. Re-Appointment of Mrs. (Dr.) Savita (DIN: 08764773) as an Independent Director.
    Special
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.25%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

  7. Re-appointment of Mr. Sanjay Suri (DIN: 00041590) as a Whole-Time Director.
    SpecialPromoters have an interest in it
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.26%

    Turnout: all 42.74% · promoters 96.97% · institutions 27.35% · other public 11.91%

  8. Extension of time for hiving off Medical Devices Business of the company, a material related party transaction, into Morepen Medipath Limited (formerly known as Morepen Medtech Limited), subsidiary company as a going concern on slump sale basis.MoreLess
    SpecialPromoters have an interest in it
    88.80% for11.20% against

    Against: promoters 0.00% · institutions 97.88% · other public 0.29%

    Turnout: all 8.06% · promoters 0.00% · institutions 27.35% · other public 11.73%

  9. Salary to Ms. Aanandi Suri, a relative of Mr. Sanjay Suri, Whole-Time Director, holding office or place of profit.
    OrdinaryPromoters have an interest in it
    97.89% for2.11% against

    Against: promoters 0.00% · institutions 97.47% · other public 0.29%

    Turnout: all 42.61% · promoters 96.59% · institutions 27.35% · other public 11.91%

  10. Salary to Mr. Arjun Suri, a relative of Mr. Sushil Suri, Chairman & Managing Director, holding office or place of profit.
    OrdinaryPromoters have an interest in it
    97.88% for2.12% against

    Against: promoters 0.00% · institutions 97.47% · other public 0.28%

    Turnout: all 42.40% · promoters 96.01% · institutions 27.35% · other public 11.91%

  11. Conversion of loan into shares or convertible instruments or other securities of the company.
    Special
    98.51% for1.49% against

    Against: promoters 0.00% · institutions 69.97% · other public 0.27%

    Turnout: all 43.75% · promoters 99.79% · institutions 27.35% · other public 11.91%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Extraordinary general meeting, 10 Feb 2025, 1 resolution

4,52,876 shareholders on the register on 3 Feb 2025; present: 27 promoters and 32 others; votes counted by Praveen Dua / P D and Associates.The company's voting result (opens in a new tab)

  1. Approval for Hive-off of Medical Devices Business of the Company into Morepen Medtech Limited, subsidiary company as a going concern on slump sale basis
    SpecialPromoters have an interest in it
    86.40% for13.60% against

    Against: promoters 0.00% · institutions 99.78% · other public 1.42%

    Turnout: all 8.50% · promoters 0.00% · institutions 27.35% · other public 12.30%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 28 Sep 2024, 6 resolutions

Present: 27 promoters and 43 others.The company's voting result (opens in a new tab)

  1. Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2024 together with the reports of the Directors’ and Auditors’ thereon.MoreLess
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.03%

    Turnout: all 43.89% · promoters 99.79% · institutions 21.48% · other public 12.31%

  2. Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    OrdinaryPromoters have an interest in it
    99.92% for0.08% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.45%

    Turnout: all 43.92% · promoters 99.79% · institutions 22.23% · other public 12.31%

  3. Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.07%

    Turnout: all 43.91% · promoters 99.79% · institutions 22.23% · other public 12.29%

  4. Re-appointment of Mr. Praveen Kumar Dutt (DIN: 06712574) as an Independent Director.
    Special
    99.70% for0.30% against

    Against: promoters 0.00% · institutions 12.90% · other public 0.14%

    Turnout: all 43.91% · promoters 99.79% · institutions 22.23% · other public 12.29%

  5. Appointment of Mr. Ranjit Khattar (DIN: 00726997) as an Independent Director.
    Special
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.21%

    Turnout: all 43.91% · promoters 99.79% · institutions 22.23% · other public 12.29%

  6. Appointment of Mr. Sharad Jain (DIN: 06423452) as an Independent Director.
    Special
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.05%

    Turnout: all 43.91% · promoters 99.79% · institutions 22.23% · other public 12.29%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Extraordinary general meeting, 18 Mar 2024, 1 resolution

Present: 26 promoters and 36 others.The company's voting result (opens in a new tab)

  1. Approval to raise capital by way of a qualified institutions placement to eligible investors through an issuance of equity shares or other eligible securities for an amount aggregating up-to Rs. 350,00,00,000/- (Rupees Three Hundred Fifty Crore Only).MoreLess
    Special
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.19%

    Turnout: all 47.03% · promoters 98.85% · institutions 23.40% · other public 14.41%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 28 Sep 2023, 5 resolutions

Present: 26 promoters and 51 others.The company's voting result (opens in a new tab)

  1. Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2023 together with the reports of the Directors' and Auditors' thereon.MoreLess
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.24%

    Turnout: all 47.35% · promoters 99.44% · institutions 22.15% · other public 14.71%

  2. Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    OrdinaryPromoters have an interest in it
    98.06% for1.94% against

    Against: promoters 0.00% · institutions 93.76% · other public 1.79%

    Turnout: all 46.72% · promoters 97.69% · institutions 23.34% · other public 14.71%

  3. Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    Ordinary
    99.88% for0.12% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.67%

    Turnout: all 47.39% · promoters 99.44% · institutions 23.34% · other public 14.71%

  4. Approval of remuneration paid/ payable to Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director from 1st April 2023 to 19th October 2023.
    SpecialPromoters have an interest in it
    97.87% for2.13% against

    Against: promoters 0.00% · institutions 93.27% · other public 2.77%

    Turnout: all 46.31% · promoters 96.62% · institutions 23.34% · other public 14.71%

  5. Re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director.
    SpecialPromoters have an interest in it
    97.97% for2.03% against

    Against: promoters 0.00% · institutions 93.27% · other public 2.22%

    Turnout: all 46.31% · promoters 96.62% · institutions 23.34% · other public 14.71%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 27 Sep 2022, 7 resolutions

Present: 23 promoters and 37 others.The company's voting result (opens in a new tab)

  1. Consideration and Adoption of audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2022 together with the reports of the Directors’ and Auditors’ thereon.MoreLess
    Ordinary
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.09%

    Turnout: all 44.20% · promoters 95.83% · institutions 12.28% · other public 14.39%

  2. Appointment Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    OrdinaryPromoters have an interest in it
    98.19% for1.81% against

    Against: promoters 0.00% · institutions 99.93% · other public 1.60%

    Turnout: all 43.59% · promoters 93.97% · institutions 12.96% · other public 14.46%

  3. Appointment of M/s. S. P. Babuta & Associates, Chartered Accountants (FRN: 007657N), as Statutory Auditors of the company and to fix their remuneration.
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.58%

    Turnout: all 44.28% · promoters 95.83% · institutions 12.96% · other public 14.46%

  4. Re-appointment of Mr. Sanjay Suri (DIN: 00041590) as a Whole-Time Director.
    SpecialPromoters have an interest in it
    98.11% for1.89% against

    Against: promoters 0.00% · institutions 99.93% · other public 1.97%

    Turnout: all 43.61% · promoters 93.97% · institutions 12.96% · other public 14.49%

  5. Alteration to the ‘Capital Clause’ of the Memorandum of Association of the company.
    Ordinary
    99.95% for0.05% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.27%

    Turnout: all 44.25% · promoters 95.83% · institutions 12.96% · other public 14.42%

  6. Alteration to the Article of Association of the company.
    Special
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.32%

    Turnout: all 44.24% · promoters 95.83% · institutions 12.96% · other public 14.39%

  7. Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    Ordinary
    99.95% for0.05% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.27%

    Turnout: all 44.24% · promoters 95.83% · institutions 12.96% · other public 14.39%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Extraordinary general meeting, 5 Mar 2022, 1 resolution

Present: 22 promoters and 34 others.The company's voting result (opens in a new tab)

  1. Variation of rights of existing Optionally Convertible Preference Shares (“OCPS”) and Cumulative Redeemable Preference Shares (“CRPS”) i.e., from OCPS and CRPS to Compulsorily Convertible Preference Shares (“CCPS”)MoreLess
    Special
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 48.03% · promoters 98.77% · institutions 28.34% · other public 21.01%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.

Mutual fund votes, meeting of 6 Sep 2025, 2 fund houses

  • Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2025 together with the reports of the Directors' and Auditors' thereon.MoreLess
    2 for0 against
  • Declaration of the final dividend of ₹0.20/- per equity share of the face value of ₹2/- each, for the financial year ended 31st March 2025.
    2 for0 against
  • Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for reappointment.
    2 for0 against
  • Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    2 for0 against
  • Appointment of M/s. PD and Associates, Company Secretaries as Secretarial Auditor of the company for a term of five (5) consecutive years and fixation of remuneration thereof.
    2 for0 against
  • Re-Appointment of Mrs. (Dr.) Savita (DIN: 08764773) as an Independent Director.
    2 for0 against
  • Re-appointment of Mr. Sanjay Suri (DIN: 00041590) as a Whole-Time Director.
    2 for0 against
  • Extension of time for hiving off Medical Devices Business of the company, a material related party transaction, into Morepen Medipath Limited (formerly known as Morepen Medtech Limited), subsidiary company as a going concern on slump sale basis.MoreLess
    Against Bandhan Mutual Fund
    • Bandhan Mutual Fund"The medical devices division contributes about one-third of the company’s revenue and has delivered double-digit growth over the past five years. On investor calls, the company has noted that this business has grown faster than the pharmaceutical segment. Despite its strong performance, the company had proposed in February 2025 to hive off the business into a subsidiary for a lump-sum consideration of ~Rs. 1.8 bn. In FY25, the division generated ~Rs. 5.0 bn in revenue, implying a transfer at a valuation of only one-third of annual revenue. Promoters initially held 20% in the subsidiary. Following a rights issue in which the company did not fully subscribe, while promoters did, the company’s stake reduced from 80% to 60%. Effectively, the company is ceding control of a high-growth business to promoters, at a significant undervaluation. 99.8% of the instituitonal investors who polled, voted against the original transaction in February 2025. We do not support the divestment and thus, do not support the extention of timeline."
    1 for1 against
  • Salary to Ms. Aanandi Suri, a relative of Mr. Sanjay Suri, Whole-Time Director, holding office or place of profit.
    Against Bandhan Mutual Fund
    • Bandhan Mutual Fund"Ms. Aanandi Suri holds a Bachelor of Science in Business from New York University’s Leonard N. Stern School of Business, with concentrations in Computing & Data Science and Marketing. She was appointed as Country Head (USA) for the API division on 22 January 2024 at an annual remuneration of Rs. 2.4 mn. Her current remuneration is Rs. 3.0 mn per annum. With effect from 1 October 2025, the company proposes to increase her maximum remuneration limit to Rs. 6.0 mn per annum. The company has about ten individuals in office of profit positions, which is high. The audit committee has approved maximum remuneration limits of Rs. 241.6 mn for promoter relatives (including office of profit positions), as per stock exchange disclosures. In addition, promoter-directors are eligible for maximum pay of Rs. 190.0 mn. Taken together, the overall remuneration ceiling for promoters is very high relative to the company’s size. The company should have disclosed how her proposed remuneration has been benchmarked against professionals with a similar background and comparable years of experience. In the absence of such disclosures, we do not support the resolution."
    1 for1 against
  • Salary to Mr. Arjun Suri, a relative of Mr. Sushil Suri, Chairman & Managing Director, holding office or place of profit.
    Against Bandhan Mutual Fund
    • Bandhan Mutual Fund"Mr. Arjun Suri graduated from Cornell University in 2021 with a Bachelor of Science in Operations Research and Industrial Engineering. He has four years of post-qualification experience, having worked with EY as a Technology Consultant and with Athene, a financial services firm, in derivative trading. He was appointed in August 2024 as Manager – Business Development, Medipath Division, and is responsible for expanding the company’s medical devices portfolio globally. His initial annual remuneration of Rs. 2.6 mn was revised to Rs. 3.0 mn. The company now seeks approval to increase his maximum remuneration limit to Rs. 6.0 mn per annum. The company has about ten individuals in office of profit positions, which is high. The audit committee has approved maximum remuneration limits of Rs. 241.6 mn for promoter relatives (including office of profit positions), as per stock exchange disclosures. In addition, promoter-directors are eligible for maximum pay of Rs. 190.0 mn. Taken together, the overall remuneration ceiling for promoters is very high relative to the company’s size. The company should have disclosed how his proposed remuneration has been benchmarked against professionals with a similar background and comparable years of experience. In the absence of such disclosures, we do not support the resolution."
    1 for1 against
  • Conversion of loan into shares or convertible instruments or other securities of the company.
    2 for0 against

Mutual fund votes, meeting of 10 Feb 2025, 2 fund houses

  • Approval for Hive-off of Medical Devices Business of the Company into Morepen Medtech Limited, subsidiary company as a going concern on slump sale basis
    2 for0 against
4 earlier meetings

Mutual fund votes, meeting of 28 Sep 2024, 2 fund houses

  • Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2024 together with the reports of the Directors’ and Auditors’ thereon.MoreLess
    2 for0 against
  • Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    2 for0 against
  • Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    2 for0 against
  • Re-appointment of Mr. Praveen Kumar Dutt (DIN: 06712574) as an Independent Director.
    2 for0 against
  • Appointment of Mr. Ranjit Khattar (DIN: 00726997) as an Independent Director.
    2 for0 against
  • Appointment of Mr. Sharad Jain (DIN: 06423452) as an Independent Director.
    2 for0 against

Mutual fund votes, meeting of 18 Mar 2024, 1 fund house

  • Approval to raise capital by way of a qualified institutions placement to eligible investors through an issuance of equity shares or other eligible securities for an amount aggregating up-to Rs. 350,00,00,000/- (Rupees Three Hundred Fifty Crore Only).MoreLess
    1 for0 against

Mutual fund votes, meeting of 28 Sep 2023, 1 fund house

  • Consideration and adoption of the audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2023 together with the reports of the Directors' and Auditors' thereon.MoreLess
    1 for0 against
  • Appointment of a director in place of Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    1 for0 against
  • Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    1 for0 against
  • Approval of remuneration paid/ payable to Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director from 1st April 2023 to 19th October 2023.
    1 for0 against
  • Re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director.
    1 for0 against

Mutual fund votes, meeting of 27 Sep 2022, 1 fund house

  • Consideration and Adoption of audited financial statements, including consolidated financial statements, of the company for the financial year ended 31st March 2022 together with the reports of the Directors’ and Auditors’ thereon.MoreLess
    1 for0 against
  • Appointment Mr. Sanjay Suri (DIN: 00041590), who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment.
    1 for0 against
  • Appointment of M/s. S. P. Babuta & Associates, Chartered Accountants (FRN: 007657N), as Statutory Auditors of the company and to fix their remuneration.
    1 for0 against
  • Re-appointment of Mr. Sanjay Suri (DIN: 00041590) as a Whole-Time Director.
    1 for0 against
  • Alteration to the ‘Capital Clause’ of the Memorandum of Association of the company.
    1 for0 against
  • Alteration to the Article of Association of the company.
    1 for0 against
  • Ratification of remuneration of M/s. Vijender Sharma & Co., Cost Accountants, as Cost Auditors of the company.
    1 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Tax disputes and stakes in unlisted companies

Reported in the filing for the quarter to Sep 2026.

  • Unlisted stake heldMorepen RX LimitedSince 6 Aug 2026

    0.00% bought in the quarter; holding 100.00%, from 100.00%

  • Tax disputeOffice of the Commissioner, Central GST & Central Excise Commissionerate, ShimlaSince 27 Dec 2025
    The Hon’ble High Court of Himachal Pradesh at Shimla, vide its judgment and order dated 12-10-2026, quashed the Show Cause Notice issued by the Office of the Commissioner, Central GST & Central Excise Commissionerate. Accordingly, the Hon’ble High Court disposed of the writ petition in favour of the Company.MoreLess
    At the filing before: As on 30-6-2026, a stay granted by the Hon'ble High Court of Himachal Pradesh at Shimla on 6-1-2026 still continued. Further, the matter was listed before the Hon'ble Court on 28-5-2026, adjourned to 7-7-2026, followed by 17-8-2026. Therefore, till the date of this report, the matter is pending for adjudication.MoreLess

In the company's own words, from its latest governance filing.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
Yes
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
Yes
There was a cyber security incident in the quarter
No

The company's own answers in its filing.